Cvijic Christine Mikail 4

What Happened

• Christine Mikail Cvijic, President and Chief Financial Officer of Neurogene Inc., sold 4,800 shares on 2026-02-27 in an open-market sale. The reported weighted-average price was $25.11 per share (range $25.00–$25.325), for total proceeds of $120,526. This was a sale (routine disposition) executed under a pre-established 10b5-1 trading plan.

Key Details

• Transaction date and price(s): 2026-02-27; weighted-average price $25.11; individual trade prices ranged $25.00–$25.325.
• Shares sold: 4,800; Transaction code: S (sale).
• Ownership after transaction: The Form 4 does not state a single total of shares beneficially owned after this sale. It discloses remaining unvested restricted stock units totaling 63,569 (21,269 + 20,300 + 22,000) with specified future vesting dates, and notes 19,200 shares are held jointly by Ms. Cvijic and her spouse, David Cvijic.
• Notable footnotes: (1) Sale was effected pursuant to a 10b5-1 plan adopted Aug 18, 2025; shares sold were held jointly with spouse. (2) Price reported is a weighted average; the filer can provide a breakdown of number of shares sold at each price upon request.
• Filing timeliness: Transaction reported on Form 4 filed 2026-03-03 for a 2026-02-27 trade; this filing date is within the typical two-business-day reporting window and is treated as timely.

Context

• This was an open-market sale under a 10b5-1 plan, which is a pre-arranged trading program that allows insiders to sell shares on a set schedule and is generally considered a routine disposition rather than a spontaneous signal about company prospects. No options were exercised and no gifts were reported in this filing.